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Background: Recent findings on genetic changes in uterine leiomyomas suggest these benign tumors being a
heterogeneous group of diseases in terms of molecular pathogenesis with those showing karyotype alterations as
well as those characterized only by cytogenetically invisible mutations of mediator subcomplex 12 (MED12). Herein,
five uterine leiomyomas (UL) with an apparently normal karyotype that lacked MED12-mutations were investigated
by copy number variation arrays along with their matching myometrium to search for small genomic imbalances.
Results: Of five tumors one showed chromothripsis-like phenomena with numerous gains and losses of small segments
mainly clustered to five chromosomal regions i.e. 2p14-2pter, 2q33.1-2q37.3, 5q31.3-5qter,11q14.1-11qter, and
18p11.21-18q2.3. Apparently, these cells had escaped detection by classical cytogenetics. Histologically, the tumor
presented as a cellular leiomyoma with extended hyalinization. Of the remaining four tumors, one had a small intragenic
deletion of the HMGA2 gene that was lacking in the corresponding myometrium. The other three tumors did not show
relevant copy number alterations at all.
Conclusions: Overall, the results suggest that leiomyomas with an apparently normal karyotype based on classical
cytogenetics and lacking MED12 mutations represent a heterogeneous group of diseases. While the HMGA2 deletion
detected in one of the tumors likely represents the driver mutation and, due to its size, has escaped detection by
classical cytogenetics, the extended genomic imbalances detected in one of the other cases cannot be overlooked by
this method suggesting an inability of the affected cells to divide in vitro. Of particular interest in that case is the
occurrence of so-called “chromothripsis” or “firestorms” without involvement of the loci of common chromosomal
rearrangements in UL, as e.g. 12q14 ~ 15 and 6p21. While chromothripsis was initially described as a hallmark of
malignancy, the etiology and significance of this phenomenon in benign tumors still remain obscure. In uterine
smooth muscle tumors, these changes per se do not indicate malignancy.
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Table 1 Patients age, size of the tumor, and karyotype
after classical cytogenetics of five randomly selected
uterine leiomyomas lacking cytogenetically detectable
karyotype alterations as well as MED12-mutation of the
“leiomyomas-type” as first described by Mäkinen et al. [1]
Case Patients age Tumorsize [cm] Karyotype
My 605 45 n.d. 46,XX [22]
My 620-2 45 3.5 46,XX [16]
My 678 43 1.3 46,XX [20]
My 708-2 42 5 46,XX [20]
My706 43 3.5 46,XX [18]
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Uterine leiomyomas are highly frequent gynaecological
tumors. Genetic changes confined to the tumor tissue and
lacking in adjacent myometrial tissue offer a highly valu-
able tool to shed light on the molecular pathogenesis of
the disease. Moreover, they may help to understand path-
ways of malignant transformation either occurring in pre-
existing leiomyomas or following an independent route of
tumorigenesis. Recent data suggest that both pathways
may account for a considerable percentage of leiomyo-
sarcomas. The ongoing discussion on the risk of iatrogenic
metastatic spreading of incidental leiomyosarcomas by
powermorcellation underscores the unmet medical need
to define and find suitable biomarkers in that field.
The vast majority of uterine leiomyomas (UL) either
display clonal karyotype aberrations detected by classical
cytogenetics or mutations of Mediator Subcomplex 12
(MED12) [1,2], or both. Besides rare cases of germline
mutations of the Fumarate Hydratase (FH) gene [3] associ-
ated with an early onset of cutaneous and uterine UL as
well as with renal cancer or of Col genes [4], two frequent
types of independent somatic driver mutations have been
deduced i.e. rearrangements of high mobility group protein
gene 2 (HMGA2) [5] and, much more frequently those af-
fecting MED12 [1]. Apparently, these both mutations do
not overlap with each other [2,4] and seem to be associated
with different tumor sizes [1,2] as well as with their pres-
ence as multiple versus solitary tumors (Markowski et al.,
in press). Moreover, MED12 mutated UL but not those
with HMGA2 rearrangements apparently display strong
growth disadvantages in vitro [6] while, in rare cases,
they may undergo malignant transformation following
an UL-STUMP (smooth muscle tumor of uncertain ma-
lignant potential)-leiomyosarcoma sequence as witnessed
by leiomyosarcomas and STUMP carrying MED12 muta-
tions [7-11]. However, having identified those leiomyomas
carrying MED12 mutations or/and cytogenetic abnormal-
ities, there remains a small percentage of 10-15% of leio-
myomas without these abnormalities. Recently, we have
described one such tumor displaying nearly genome-wide
uniparental disomy with some additional genetic alterations
that was histologically classified as an epithelioid leiomyo-
mas [12]. This case encouraged us to investigate further
leiomyomas remaining without MED12 mutations but with
an apparently normal karyotype.
Herein, we have examined five of these cases along with
corresponding myometrial tissue by CNV (copy number
variation) arrays. The results revealed genetic alterations in
2/5 tumors which in one of the cases only corresponds to
with the locus of a previously identified driver mutation. In
another case, the analysis leads to the identification of gross
genetic rearrangements that apparently had escaped detec-
tion by conventional cytogenetics. The significance of these
findings in term of molecular pathogenesis is discussed.Results
Five uterine leiomyomas (UL) were investigated by CNV-
arrays along with their matching myometrium (Table 1).
All these UL lacked karyotypic abnormalities as detected
by classical cytogenetics as well as MED12 mutations in
the hot spot region as initially described by Mäkinen et al..
Accordingly, four of the tumors did not reveal gross copy
number alterations after CNV-analysis (Figure 1A, B). In
contrast, in one tumor (My 708-2) numerous deletions
were seen while the myometrial tissue did not show these
deletions (Figures 1C and 2A). Interestingly, these copy
number alterations were mainly restricted to a total of five
chromosomal regions i.e. 2p14 → 2pter, 2q33.1 → 2q37.3,
5q31.3→ 5qter, 11q14.1→ 11qter, and 18p11.21→ 18q2.3
(Figure 2B-F). Across these five parts of the genome it was
possible to detect at least 145 distinct regions of copy num-
ber alterations ranging in size between 43 and 13,647,027
kbp. On the other hand, in that case classical cytogenetics
on a 275 to 550 bands/haploid set-level revealed an appar-
ently normal karyotype 46,XX in all 20 metaphases exam-
ined (Figure 3A). Histologically, the tumor presented as
a cellular leiomyoma with large areas of hyalinization
(Figure 3B, C).
Aimed at the detection of small copy number alterations
we have then performed a detailed comparison of the copy
number profiles of leiomyomas vs. myometrial tissue in
the remaining four cases. Interestingly, one of the tumors
(My 706) showed a small deleted region within intron 4 of
the HMGA2 gene. This deletion had a size of approxi-
mately 6 kbp and was lacking in the corresponding normal
smooth muscle tissue (Figure 4). In the other tumors, even
the detailed comparison did not reveal evidence for the
presence of copy number alterations that were lacking in
the matching myometrial tissue.
Discussion
There is convincing evidence that recurrent types of
Mediator Subcomplex 12 (MED12) mutations and rear-
rangements of the HMGA2 locus at 12q14 ~ 15 leading
to its transcriptional upregulation represent the two largest
groups of independent driver mutations in UL [2,4].
Figure 1 Copy number variation (CNV)-array analysis of two leiomyomas without gross copy number alterations (A: My 678, B: My 706)
and one leiomyomas showing multiple genomic losses within five genomic regions (C: My 708) that were absent in the matching
myometrial tissue (C: myometrium).
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than their MED12-mutated counterparts [1,2] and prefer-
entially occur in larger, solitary lesions [13]. Moreover, in
contrast to UL cells harboring MED12 mutations, cells
with HMGA2-rearrangements, as a rule, seem to be able
to survive in vitro for numerous passages [6].
In a considerable percentage of UL neither chromosomal
rearrangements of the HMGA2 locus nor clonal karyotypic
deviations in general nor MED12 mutations are found.
This percentage can be estimated to be approximately
15% and includes cases with rare driver mutations such
as e.g. deletions of the FH-locus [4]. Nevertheless, even
after having deleted these rare mutations there remain
some 10% of UL with presumably unknown driver muta-
tions. It seems reasonable to assume that these cases are
more frequent among histologically variant UL as e.g.suggested by an epithelioid UL displaying copy number
neutral loss of heterozygozity for large parts of its gen-
ome [12] that mechanistically has been explained by
secondary duplication of the genome of a hyper-haploid
tumor. To extend this study and aimed at the detection
of copy number alterations confined to the tumor tissue
the present study describes the results of a CNV ana-
lysis of five UL along with matching myometrial tissue.
These possible genomic imbalances might help to uncover
rare novel driver mutations. Interestingly, one of the tu-
mors presented with only one small deletion undetectable
by classical cytogenetics due to its small size which was
absent from the matching myometrium. Nevertheless,
this deletion was mapped to the fourth intron of the
HMGA2 gene suggesting it being a driver mutation
comparable to the gross and cytogenetically visible
Figure 2 Leiomyoma (#708) with extended copy number alterations confined to four distinct chromosomal regions and the whole
chromosome 18, respectively. A: Genomic view of the case showing for each chromosome the ideogram, the myometrial tissue (light blue line),
and the leiomyomas (dark blue line). Red blocks represent deletions. B-F: Detailed view of the five parts of the genome showing numerous
losses, i.e. 2p14 → 2pter, 2q33.1→2qter, 5q31.3→5qter, 11q14.1→11qter, and 18p11.21→18q22.3. Within each diagram the two lines above
the ideogram represent myometrial tissue (light blue) and the leiomyoma (dark blue), respectively. Dashed lines and numbers represent the
map positions according to Hg19 (NCBI Build 37 reference sequence). In the top line, the positions of deletions are shown as red blocks.
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Figure 3 Histologic appearance and cytogenetic analysis of tumor 708–2. Histologic appearance after H&E staining reveals a cell-rich
leiomyoma with extended hyalinization. A: Overview. B,C: Histology at larger magnification. D: Representative G-banded karyotype at a level of
approximately 350 bands/haploid set.
Figure 4 Copy number alterations indicating a small intragenic deletion within the HMGA2 gene, case #706, dotted line. LM and blue
squares: leiomyomas tissue, yellow squares: myometrial tissue. Bottom line: genomic structures of the HMGA2 gene with vertical bars indicating
exons based on [5].
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mal subset of UL.
In contrast, one of the other fibroids revealed multiple
genomic deletions of different sizes that should not have
escaped detection by cytogenetics. The most plausible
explanation for the apparently normal karyotype in that
case is that the tumor cells did not proliferate in vitro as
recently also documented for UL carrying MED12 muta-
tions [6]. In general, this tumor showed genomic alter-
ations resembling a particular type of genetic damage
identified by Stephens et al. [14]. They coined the name
chromothripsis to describe massive genomic rearrange-
ments that likely originate from one single catastrophic
event. Even earlier, the same phenomenon has been de-
scribed in breast cancer by Hicks et al. [15] who described
the occurrence multiple closely spaced “firestorms” in a
large percentage of breast cancer samples where it was
found to be associated with an adverse prognosis in both
node negative and positive tumors.
However, as a typical sign of “firestorms” or “chro-
mothripsis” the rearrangements are confined to well-
circumscribed regions of chromosomes instead of being
spread across the whole genome. In contrast, the remaining
part of the genome appears to be rather “quiet”. While
initially described in hematological malignancies [14,16]
and some solid cancers as in particular sarcomas and
carcinomas [14,15,17], in a recent study Mehine et al.
[4] were able to show that chromothripsis-like rearrange-
ments do also occur in uterine leiomyomas. Again a dras-
tically reduced ability of some leiomyomas to proliferate
in vitro may account for the lack of detection of these
massive genomic rearrangements by classical cytogen-
etics though highly complex genomic rearrangements
in leiomyomas are occasionally found by conventional
cytogenetics. However, the low resolution obtained has
certainly hindered to recognize the ‘true complexity’ in
these latter cases. As a rule, in chromothripsis the multiple
rearrangements are correlated with multiple copy number
alterations [18]. Typically, the characteristic changes ob-
served reflect that the process causing this massive but
localized breakage has been resolved in the absence of
ongoing genomic instability. In the cases presented by
Mehine et al. [4] no evidence for atypic or variant UL
has been reported. Thus, chromothripsis is not likely to
affect exclusively malignant cells and accordingly foot-
prints of resolved chromothripsis do not necessarily ac-
company malignant transformation. In line with this
finding, the case described herein shows chromothrip-
sis apparently in the absence of rearrangements of loci
harboring known driver genes and the regions affected
by massive rearrangements do not coincide with those
shown to be frequently affected by firestorms in breast can-
cer [15]. While, the tumor presented as a variant leiomyoma
upon histological examination it clearly shows thatseverely disturbed array profiles do not indicate malig-
nancy per se.
As to the molecular pathogenesis of atypical leiomyomas,
STUMP, and leiomyosarcomas in a recent paper [19] as
well as Zhang et al. [20] were able to show that MED12
mutations are significantly less common in atypical than
in ordinary leiomyomas. Along with our data presented
herein and a further case previously reported [12] this
may suggest that among the atypical leiomyomas unusual
pathways of molecular pathogenesis are overrepresented.
In summary, the molecular genetics of atypical leiomyomas
constitutes a future challenge for the understanding and
diagnosis of these tumors. At least a subset of these tumors
may represent variant leiomyomas that had arisen follow-
ing unorthodox genetic pathways. It remains to be deter-
mined if some of these pathways may predispose the
variant UL to undergo malignant transformation.Conclusions
Apparently, “double negative” leiomyomas, i.e. those lack-
ing clonal cytogenetic derivations as detected by classical
cytogenetics as well as MED12 mutations represent a
heterozygous group of tumors. Within that group, CNV
arrays offer a suitable tool to identify gross genetic abnor-
malities which had escaped detection by cytogenetics due
to the inability of the cells to survive in vitro. These latter
abnormalities may be often occurring among histologically
variant leiomyomas thus pointing to rare pathways of
molecular pathogenesis. Nevertheless, as such severely
disturbed CNV patterns cannot be used to diagnose
malignancy.Methods
Tissue samples
Tumor samples and adjacent myometrial tissue snap fro-
zen in liquid nitrogen immediately after surgery (<20 min)
were used for array analyses. For all samples corresponding
myometrial tissue of the patients has been taken and inves-
tigated as well. The study was approved by the local ethics
committee (Ethikkommission der Bremer Ärztekammer)
and informed written consent was obtained from all patients
prior to surgery.Histologic examination
For diagnostic purposes tumor samples were fixed in
paraformaldehyde (4% in PBS) and processed for paraffin
embedding. Tissue sections (1-2 μm thickness) were depar-
affinized in xylene, rehydrated through a series of ethanol,
and stained with hematoxylin and eosin (H&E) for histo-
logic examination. Classification was based on the World
Health Organization classification of tumors of female
reproductive organs [21].
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Chromosome analyses of cell cultures were performed
following routine techniques as described earlier [22]. At
least 20 metaphases/case were fully karyotyped.
DNA isolation
DNA from the frozen tissue samples was isolated using
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
on a QIACube (Qiagen) according to the manufacturer’s
instructions.
PCR and sequencing
For PCR amplification 1000 ng of genomic template DNA
were used. Primers to amplify the desired human PCR
fragment of the MED12 gene were those recently de-
scribed [1,2]. Subsequently, PCR-products were separated
by agarose gel-electrophoresis and the desired DNA-
fragments/-bands were extracted by a QIAquick Gel
Extraction Kit (Qiagen) using a QIACube (Qiagen) ac-
cording to manufacturer’s instructions. DNA-sequencing
of the purified PCR-products was performed by GATC
Biotech (Konstanz, Germany).
RNA isolation
Total RNA from frozen tissue samples was isolated using
a RNeasy Mini Kit (Qiagen) on a QIACube (Qiagen)
according to manufacturer’s instructions and DNase I
digestion was performed.
cDNA-synthesis
250 ng of total RNA were reverse transcribed with M-MLV
reverse transcriptase (Invitrogen, Karlsruhe, Germany),
RNase Out (Invitrogen), random hexamers and dNTPs
according to the manufacturer’s instructions. RNA was
denatured at 65°C for 5 min and subsequently kept on
ice for 1 min. After adding the enzyme to the RNA primer
mixes, samples were incubated for 10 min at 25°C to allow
annealing of the random hexamers. Reverse transcription
was performed at 37°C for 50 min followed by inactivation
of the reverse transcriptase at 70°C for 15 min.
Quantitative real-time PCR
Relative quantification of transcription levels was carried
out by real-time PCR analyses using the Applied Biosys-
tems 7300 Real-Time PCR system (Applied Biosystems,
Darmstadt, Germany). For quantification of HMGA2
mRNA (Hs00171569) a commercially available gene ex-
pression assay (Applied Biosystems) was used. HPRT served
as endogenous control as described before [23].
Arrays
CNV (copy number variation) analysis was performed
using premade CytoScan HD Arrays (Affymetrix, Santa
Clara, CA) consisting more than 2.4 million markersfor copy number and approximately 750,000 single nu-
cleotide polymorphisms (SNPs). Enriched gene coverage
for cancer and constitutional genes results in a marker-
base ratio coverage of 1/384 for ISCA, 1/553 for cancer
genes, 1/486 for X-chromosomal genes and 1/659 for
12,000 OMIM genes. The manufacturer’s instructions were
followed for labelling of 250 ng DNA, and hybridization.
After staining and washing using a GeneChip Fluidics
Station 450 (Affymetrix) the arrays were scanned by an
Affymetrix 3000 7G scanner. Arrays were analysed through
the Affymetrix Chromosome Analysis Suite (ChAS)
software (ChAS analysis files for the CytoScan® HD Array
version NA32.3). Numbering of map positions was based
on hg19 (NCBI Build 37 reference sequence).
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